Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum for Advanced NSCLC
The aim of this study is to explore the Clinical Value of Sequential Gefitinib With Pemetrexed/Platinum compare with Pemetrexed/Platinum for Advanced NSCLC.
NSCLC
DRUG: Sequential Gefitinib With Pemetrexed/Platinum|DRUG: Pemetrexed/Platinum
12 weeks of non-progression rate, from the first cycle of treatment (day one) to two month after the last cycle
PFS, from the first cycle of treatment (day one) to two month after the last cycle
Patients will be randomized to 2 groups